Literature DB >> 33278012

Pemafibrate prevents retinal neuronal cell death in NMDA-induced excitotoxicity via inhibition of p-c-Jun expression.

Naoki Fujita1,2, Kana Sase2, Chihiro Tsukahara2, Ibuki Arizono1,2, Hitoshi Takagi2, Yasushi Kitaoka3.   

Abstract

Excitotoxicity is involved in the retinal neuronal cell death in diabetic retinopathy. Although fenofibrate has been shown to ameliorate the progression of diabetic retinopathy, the effect of pemafibrate, which is highly selective for peroxisome proliferator-activated receptor α on retinal neuronal cell death has not been documented. Here, we investigated whether pemafibrate exerts a beneficial effect against retinal ganglion cell (RGC) death induced by N-methyl-D-aspartate (NMDA) in rats. Experiments were performed on adult male Wistar rats that received an intravitreal injection of 20 nmol NMDA. Fluoro-Gold labeled RGC morphometry showed that oral intake of pemafibrate once a day for 7 days resulted in significant protection on RGC death induced by NMDA. Phosphorylated c-Jun protein, which is involved in apoptosis, was upregulated after NMDA exposure, and this increase was significantly lessened by the systemic pemafibrate treatment. Phosphorylated c-Jun immunopositive cells were colocalized with Thy-1 immunopositive cells, and the increased these cells were ameliorated by the pemafibrate treatment. An increase in TUNEL-positive cells was significantly suppressed by the pemafibrate treatment. Phosphorylated c-Jun immunopositive cells were colocalized with TUNEL-positive cells, and they were decreased by pemafibrate treatment. These results suggest that the RGC protection achieved with pemafibrate appears to be associated with inhibition of phosphorylated c-Jun and its anti-apoptotic effect.

Entities:  

Keywords:  Apoptosis; Excitotoxicity; NMDA; PPAR-α; Pemafibrate; c-Jun

Mesh:

Substances:

Year:  2020        PMID: 33278012      PMCID: PMC7884588          DOI: 10.1007/s11033-020-06032-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

1.  Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction.

Authors:  Yang Hu; Ying Chen; Lexi Ding; Xuemin He; Yusuke Takahashi; Yang Gao; Wei Shen; Rui Cheng; Qian Chen; Xiaoping Qi; Michael E Boulton; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-03       Impact factor: 11.205

Review 2.  The mechanisms of action of PPARs.

Authors:  Joel Berger; David E Moller
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation.

Authors:  Qiuping Liu; Fengjun Zhang; Xian Zhang; Rui Cheng; Jian-Xing Ma; Jinglin Yi; Jingming Li
Journal:  Mol Cell Biochem       Date:  2017-12-21       Impact factor: 3.396

4.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

Review 5.  Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.

Authors:  Jean-Charles Fruchart
Journal:  Atherosclerosis       Date:  2009-03-20       Impact factor: 5.162

6.  The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.

Authors:  Emily Y Chew; Matthew D Davis; Ronald P Danis; James F Lovato; Letitia H Perdue; Craig Greven; Saul Genuth; David C Goff; Lawrence A Leiter; Faramarz Ismail-Beigi; Walter T Ambrosius
Journal:  Ophthalmology       Date:  2014-08-29       Impact factor: 12.079

Review 7.  Mechanism of action of fibrates on lipid and lipoprotein metabolism.

Authors:  B Staels; J Dallongeville; J Auwerx; K Schoonjans; E Leitersdorf; J C Fruchart
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

8.  Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

Authors:  Emily Y Chew; Walter T Ambrosius; Letitia T Howard; Craig M Greven; Samantha Johnson; Ronald P Danis; Matthew D Davis; Saul Genuth; Michael Domanski
Journal:  Am J Cardiol       Date:  2007-04-13       Impact factor: 2.778

9.  Protective and antioxidant effects of PPARα in the ischemic retina.

Authors:  Elizabeth Moran; Lexi Ding; Zhongxiao Wang; Rui Cheng; Qian Chen; Robert Moore; Yusuke Takahashi; Jian-xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-13       Impact factor: 4.799

Review 10.  Molecular Actions of PPARα in Lipid Metabolism and Inflammation.

Authors:  Nadia Bougarne; Basiel Weyers; Sofie J Desmet; Julie Deckers; David W Ray; Bart Staels; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

View more
  3 in total

Review 1.  Retinal Glutamate Neurotransmission: From Physiology to Pathophysiological Mechanisms of Retinal Ganglion Cell Degeneration.

Authors:  Isabella Boccuni; Richard Fairless
Journal:  Life (Basel)       Date:  2022-04-25

2.  Investigating the Mechanisms of Pollen Typhae in the Treatment of Diabetic Retinopathy Based on Network Pharmacology and Molecular Docking.

Authors:  Rongrong Zhou; Yuqing Zhang; Liyun Duan; Yuehong Zhang; Yingying Duan; Xiaomin Kang; Fengmei Lian
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-03       Impact factor: 2.629

3.  Pharmacological Inhibition of Spermine Oxidase Suppresses Excitotoxicity Induced Neuroinflammation in Mouse Retina.

Authors:  Moaddey Alfarhan; Fang Liu; Shengshuai Shan; Prahalathan Pichavaram; Payaningal R Somanath; S Priya Narayanan
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.